IN8bio (INAB) Projected to Post Quarterly Earnings on Thursday

IN8bio (NASDAQ:INAB) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect IN8bio to announce earnings of ($0.3367) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

IN8bio (NASDAQ:INAB) last announced its earnings results on Thursday, August 6th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.09. On average, analysts expect IN8bio to post ($1.49) EPS for the current fiscal year and ($1.24) EPS for the next fiscal year.

IN8bio Stock Up 6.3%

Shares of INAB stock opened at $1.02 on Thursday. The stock has a fifty day moving average of $1.16 and a 200 day moving average of $1.47. IN8bio has a 52 week low of $0.87 and a 52 week high of $2.73. The firm has a market capitalization of $10.06 million, a price-to-earnings ratio of -0.63 and a beta of 0.30.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of IN8bio in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold”.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing ?? T cell therapeutic and ?? T cell engager (TCE) product candidates to address unmet medical needs. ?? T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic ?? T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.